Median Technologies sets strategic review and R&D committees
Median Technologies says it has formed a Strategic Review Committee and an R&D Committee to unlock intrinsic value and accelerate its eyonis Pan-Cancer strategy.
Regulatory News:Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses…